NATICK, Mass., European regulators have approved an expanded indication for the Boston Scientific Corporation WATCHMAN ® Left Atrial Appendage (LAA) Closure Device. The new indication offers patients ...

As physicians and patients await news from the Centers for Medicare & Medicaid Services (CMS) regarding coverage for percutaneous left atrial appendage (LAA) closure, a new analysis suggests that it ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...

SAN FRANCISCO — Thirteen months after percutaneous left atrial appendage closure (LAAC), outcomes did not differ whether closure was performed using the Amulet (Abbott Cardiovascular) or the Watchman ...

HOUSTON, TX--(Marketwired - Jan 30, 2017) - Memorial City Cardiology Associates offers the WATCHMAN™ Left Atrial Appendage Closure Device Procedure, a breakthrough alternative to blood thinners in ...

WASHINGTON, DC — Quality-of-life scores were "modestly" but significantly better at one year in patients with atrial fibrillation (AF) if they received the Watchman (AtriTech/Boston Scientific) device ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...